Biomea, FDA and Type 2 diabetes
FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate
Friday, the FDA lifted the clinical hold on Biomea Fusion, Inc.’s (NASDAQ:BMEA) ongoing Phase 1/2 clinical trials of the company’s investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112),
Biomea’s stock bounces back as FDA lifts clinical hold on diabetes trials
The US FDA placed a full clinical hold on two diabetes trials for Biomea’s menin inhibitor after reports of liver toxicity.
US FDA lifts clinical hold on Biomea's diabetes trials after safety review
The U.S. Food and Drug Administration lifted a clinical hold on Biomea Fusion's ongoing studies of its experimental drug for type 1 and type 2 diabetes, the drug developer said on Thursday. The regulator had placed a hold on two trials of its lead drug,
BMEA Stock Up 9% as FDA Lifts Clinical Hold on 2 Diabetes Studies
Biomea stock rises 9% after the FDA lifts clinical hold on two phase I/II studies evaluating the company's lead candidate, BMF-219, for diabetes.
FDA lifts hold on diabetes trials after Biomea mitigates liver toxicity risk
Biomea Fusion has escaped from the full clinical hold imposed by the FDA. | Biomea Fusion has escaped from the full clinical hold imposed by the FDA. After reviewing the data, the regulator has cleared Biomea to study its diabetes drug candidate under a revised protocol intended to mitigate liver toxicity concerns.
Biomea Fusion: FDA Lifts Hold on Diabetes-Treatment Trials
Biomea Fusion said the Food and Drug Administration lifted its clinical hold on continuing clinical trials of the company's diabetes drug.
US FDA lifts clinical hold on Biomea's diabetes trials
Biomea Fusion said on Thursday the U.S. Food and Drug Administration lifted a clinical hold on ongoing studies of its experimental drug for type 1 and 2 diabetes, sending its shares up 6.9%. The decision comes as a boon for the company as the regulator placed a hold on two trials of its lead drug,
Biomea Fusion : FDA Lifts Clinical Hold On BMF-219 For Type 1 And Type 2 Diabetes Trials; Stock Up
Biomea Fusion Inc. (BMEA) announced that the U.S. Food and Drug Administration has lifted the clinical hold on the company's ongoing
Biomea upgraded by analysts after FDA lifts clinical hold
Biomea (BMEA) has received two analyst upgrades along with bullish comments from other firms following news the FDA has lifted a clinical hold on a study of its drug BMF-219.
Buy Rating Affirmed for Biomea Fusion with Promising BMF-219 Clinical and Regulatory Developments
Joseph Pantginis, an analyst from H.C. Wainwright, maintained the Buy rating on Biomea Fusion (BMEA – Research Report). The associated ...
bovnews7h
The Biomea Fusion Inc Stock Thriller: Decoding the Mystery Behind BMEA’s Recent Movements
On Thursday, Biomea Fusion Inc (BMEA) stock saw a modest uptick, ending the day at $9.57 which represents a slight increase of $0.80 or 9.12% from the prior close of $8.77. The stock opened at $8.98 ...
devdiscourse5h
Major Developments in Health Sector: New Drugs and Global Initiatives
The U.S. FDA approved Bristol Myers' new schizophrenia drug, the first of its kind in decades. Bavarian Nordic signed an ...
Oppenheimer Sticks to Its Buy Rating for Biomea Fusion (BMEA)
Oppenheimer analyst Matthew Biegler maintained a Buy rating on Biomea Fusion (BMEA – Research Report) today and set a price target of ...
Biomea Fusion, Inc. May Have Violated Securities Laws And The Schall Law Firm Urges Shareholder Participation In An Inquiry
NDAQ:BMEA) Biomea Fusion, Inc. May Have Violated Securities Laws And The Schall Law Firm Urges Shareholder Participation In An Inquiry ...
devdiscourse22h
Current Updates: Major Developments in Health Sector
This summary highlights major health news, including Bavarian Nordic's UNICEF agreement for mpox vaccines, Pfizer's ...
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA) and Repligen (RGEN)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biomea Fusion (BMEA – Research Report) and Repligen (RGEN – ...